title: Clinical utility of glatiramer acetate in the management of relapse frequency in multiple sclerosis.
abstract: Glatiramer acetate (GA) represents one of the most common disease-modifying therapies for multiple sclerosis. GA is currently approved for patients at high risk of developing clinically definite multiple sclerosis (CDMS) after having experienced a well-defined first clinical episode (clinically isolated syndrome or CIS) and for patients with relapsing-remitting multiple sclerosis (RRMS). GA's efficacy and effectiveness to reduce relapse frequency have been proved in placebo-controlled and observational studies. Comparative trials have also confirmed the lack of significant differences over other choices of treatment in the management of relapse frequency, and long-term studies have supported its effect at extended periods of time. Additionally, RRMS patients with suboptimal response to interferon β may benefit from reduced relapse rate after switching to GA, and those with clinically isolated syndrome may benefit from delayed conversion to CDMS. All these results, together with its proven long-term safety and positive effect on patients' daily living, support the favorable risk-benefit of GA for multiple sclerosis treatment.
authors: Department of Neurology, Hospital Regional Universitario Carlos Haya, Málaga, Spain.
authors: Oscar
authors: O
authors: Fernández
keywords: disease-modifying therapy; glatiramer acetate; multiple sclerosis; relapse
references: Neurology. 2007 Oct 2;69(14):1391-403
references: 17761550
references: Ann Neurol. 2009 Sep;66(3):403-6
references: 19798640
references: Health Qual Life Outcomes. 2008 Nov 14;6:100
references: 19014588
references: Mult Scler. 2012 Jul;18(7):932-46
references: 22249762
references: J Neurol. 2008 Sep;255(9):1378-83
references: 18584233
references: Ann Neurol. 1982 Mar;11(3):317-9
references: 7092185
references: Proc Natl Acad Sci U S A. 2008 Aug 12;105(32):11358-63
references: 18678887
references: J Neurol Neurosurg Psychiatry. 2004 Jul;75(7):1045-7
references: 15201369
references: Proc Natl Acad Sci U S A. 1994 May 24;91(11):4872-6
references: 7515181
references: Mult Scler. 2010 Mar;16(3):342-50
references: 20106943
references: Health Qual Life Outcomes. 2010 Nov 15;8:133
references: 21078142
references: Lancet. 2009 Oct 31;374(9700):1503-11
references: 19815268
references: Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):14157-62
references: 14614135
references: Eur J Neurol. 2005 Nov;12(11):817-27
references: 16241970
references: J Immunol. 2003 May 1;170(9):4483-8
references: 12707324
references: Mult Scler. 2003 Dec;9(6):585-91
references: 14664471
references: J Med Econ. 2012;15(3):424-33
references: 22217249
references: J Neurol Sci. 2012 Jan 15;312(1-2):7-12
references: 21920559
references: Mult Scler. 2008 May;14(4):494-9
references: 18208875
references: Neurology. 2006 Oct 10;67(7):1242-9
references: 16914693
references: Rev Neurol. 2011 Aug 1;53(3):129-38
references: 21748710
references: Eur J Neurol. 2006 May;13(5):471-4
references: 16722971
references: Mult Scler. 2006 Jun;12(3):309-20
references: 16764344
references: Ann Neurol. 2009 Apr;65(4):367-77
references: 19399841
references: Appl Health Econ Health Policy. 2009;7(2):91-108
references: 19731967
references: J Neurol Sci. 1977 Apr;31(3):433-8
references: 845620
references: N Engl J Med. 1987 Aug 13;317(7):408-14
references: 3302705
references: J Neuroimmunol. 1998 Dec 1;92(1-2):113-21
references: 9916886
references: J Clin Invest. 2002 Mar;109(5):641-9
references: 11877472
references: Neurosci Lett. 2006 Oct 9;406(3):270-5
references: 16934924
references: J Med Econ. 2010;13(3):464-71
references: 20662760
references: Autoimmun Rev. 2007 Aug;6(7):469-75
references: 17643935
references: Clin Ther. 2010 Jun;32(6):1061-6
references: 20637960
references: Acta Neurol Scand. 2005 Jan;111(1):42-7
references: 15595937
references: J Neuroimmunol. 2001 Apr 2;115(1-2):152-60
references: 11282165
references: J Neurol Sci. 1979 Jul;42(2):267-74
references: 90129
references: Mult Scler. 2003 Dec;9(6):592-9
references: 14664472
references: J Manag Care Pharm. 2009 Sep;15(7):543-55
references: 19739877
references: J Neurol. 2011 Mar;258(3):402-11
references: 20922405
references: Eur J Neurol. 2008 Apr;15(4):386-93
references: 18353125
references: Health Qual Life Outcomes. 2008 Sep 05;6:67
references: 18775064
references: N Engl J Med. 2006 Mar 2;354(9):899-910
references: 16510744
references: J Neurosci Nurs. 2001 Oct;33(5):231-9
references: 11668881
references: Mult Scler. 2000 Aug;6(4):255-66
references: 10962546
references: J Manag Care Pharm. 2002 Nov-Dec;8(6):469-76
references: 14740608
references: Arch Neurol. 2012 Jan;69(1):82-8
references: 22232347
references: Neurology. 2000 Feb 22;54(4):807-12
references: 10690967
references: Neurology. 2002 Nov 12;59(9):1412-20
references: 12427893
references: Ther Clin Risk Manag. 2010 Apr 15;6:153-72
references: 20421914
references: Proc Natl Acad Sci U S A. 2005 Dec 27;102(52):19045-50
references: 16365293
references: Neurology. 1995 Jul;45(7):1268-76
references: 7617181
references: Proc Natl Acad Sci U S A. 2000 Jun 20;97(13):7452-7
references: 10861011
references: Ann Neurol. 2001 Mar;49(3):290-7
references: 11261502
references: Neurology. 2009 Jun 9;72(23):1976-83
references: 19279320
references: Lancet Neurol. 2009 Jun;8(6):545-59
references: 19446274
references: Eur J Neurol. 2005 Jun;12(6):425-31
references: 15885045
references: J Manag Care Pharm. 2007 Apr;13(3):245-61
references: 17407391
references: Rev Neurol. 2012 Jan 1;54(1):1-9
references: 22187206
references: Eur J Immunol. 1971 Aug;1(4):242-8
references: 5157960
references: FASEB J. 2002 Aug;16(10):1260-2
references: 12060672
references: Brain. 2001 Sep;124(Pt 9):1803-12
references: 11522582
references: Immunol Lett. 1996 Apr;50(1-2):1-15
references: 8793553
references: CNS Drugs. 2011 May;25(5):401-14
references: 21476611
references: Brain. 2004 Jun;127(Pt 6):1370-8
references: 15090474
references: Med Hypotheses. 2007;69(1):145-8
references: 17196755
references: J Neurol. 2008 Mar;255 Suppl 1:26-36
references: 18317674
references: CNS Drugs. 2003;17(8):563-75
references: 12775193
references: Mult Scler. 2008 Jul;14(6):749-58
references: 18611988
references: J Clin Invest. 2000 Apr;105(7):967-76
references: 10749576
references: Acta Neurol Scand. 2006 Jun;113(6):378-86
references: 16674604
references: Neurol Sci. 2011 Dec;32(6):1035-41
references: 21505911
references: J Immunol. 1998 May 1;160(9):4386-97
references: 9574543
references: CNS Drugs. 2004;18(9):561-74
references: 15222773
references: J Immunol. 2004 Jun 1;172(11):7144-53
references: 15153538
references: J Neuroimmunol. 2002 Feb;123(1-2):188-92
references: 11880163
references: Drugs. 2010 Aug 20;70(12):1545-77
references: 20687620
references: Proc Natl Acad Sci U S A. 2009 Oct 20;106(42):17992-7
references: 19815532
references: Mult Scler. 2001 Feb;7(1):33-41
references: 11321192
references: J Neurol Sci. 2012 Apr 15;315(1-2):123-8
references: 22133480
references: Neurology. 2000 Feb 22;54(4):813-7
references: 10690968
references: Lancet Neurol. 2008 Oct;7(10):903-14
references: 18789766
references: J Neurosci Nurs. 2004 Jun;36(3):120-9
references: 15233411
references: J Neurol Sci. 2009 Feb 1;277 Suppl 1:S37-41
references: 19200865
references: Ann N Y Acad Sci. 1984;436:366-72
references: 6398019
references: J Neuroimmunol. 2005 Oct;167(1-2):215-8
references: 16083971
references: Proc Natl Acad Sci U S A. 2009 Mar 17;106(11):4355-9
references: 19255448
references: Clin Exp Immunol. 2006 Feb;143(2):357-62
references: 16412061
references: J Neuroimmunol. 1996 Feb;64(2):209-17
references: 8632064
references: Lancet Neurol. 2009 Oct;8(10):889-97
references: 19729344